Electra Therapeutics, Inc.
IPO of $350M

IPO of $350M
Undisclosed of $60.0M
FDA goal date for UX111 (rebisufligene etisparvovec) (BLA), for Sanfilippo syndrome type A (MPS IIIA)
FDA goal date for zidesamtinib (NDA), for TKI pre-treated locally advanced or metastatic ROS1-positive non-small cell lung cancer
Change in directors or officers
Change in directors or officers
Change in directors or officers
Change in directors or officers
Change in directors or officers